Evidence map›Paper›PMID 42446905›Full record

ArticleCancer research2026

High-Risk Rhabdomyosarcomas Feature a Convergent Cell State.

Holly J Whitfield, Nathaniel D Anderson, Christina Burke, Marian J Groot Koerkamp, Conor Parks, Toochi Ogbonnah, Yvette Wood, Alice Piapi, Emilia Robertson, Eleanor Watt and 25 more

Abstract read
In one paragraph

Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Holly J Whitfield *Wellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0000-0002-7282-387X
Nathaniel D Anderson *Wellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0000-0003-4523-6327
Christina BurkeUCL Cancer Institute, London, United Kingdom.ORCID 0000-0001-5381-3185
Marian J Groot KoerkampPrincess Máxima Center for Pediatric Oncology, Oncode Institute, Utrecht, the Netherlands.ORCID 0000-0002-0867-0821
Conor ParksWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0000-0003-0240-0684
Toochi OgbonnahWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0009-0002-7283-6758
Yvette WoodWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0009-0007-5527-5895
Alice PiapiUCL Cancer Institute, London, United Kingdom.ORCID 0000-0001-8251-3309
Emilia RobertsonUCL Cancer Institute, London, United Kingdom.ORCID 0009-0002-1740-7811
Eleanor WattUCL Cancer Institute, London, United Kingdom.ORCID 0000-0002-9571-0819
Abigail WhiteGreat Ormond Street Hospital for Children, London, United Kingdom.ORCID 0009-0008-4498-5813
Solange De NoonWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0000-0002-6380-8117
Jonathan KennedyWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0009-0002-4953-4639
Rajvi NagrechaWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0000-0003-1288-1653
Michael T MeisterPrincess Máxima Center for Pediatric Oncology, Oncode Institute, Utrecht, the Netherlands.ORCID 0000-0001-8311-721X
Ewa AladowiczInstitute of Cancer Research , Sutton, United Kingdom.ORCID 0009-0008-6664-0699
Yang Kee Stella ManInstitute of Cancer Research , Sutton, United Kingdom.ORCID 0000-0002-2082-1565
Virginia LaspideaUCL Cancer Institute, London, United Kingdom.ORCID 0000-0001-6017-7295
Mi K TrinhWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0000-0003-4185-0071
Angus HodderWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0009-0003-2577-0677
Tarryn PorterWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0000-0002-6063-0659
John E LawrenceWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0000-0002-7951-915X
Elizabeth TuckWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0000-0002-1837-7549
Trung NguyenGreat Ormond Street Hospital for Children, London, United Kingdom.ORCID 0000-0002-0082-9340
Anna KelseyRoyal Manchester Children's Hospital, Manchester Foundation Trust, Manchester, United Kingdom.ORCID 0000-0003-3638-1266
Adrienne M FlanaganUCL Cancer Institute, London, United Kingdom.ORCID 0000-0002-2832-1303
Richard HewittGreat Ormond Street Hospital for Children, London, United Kingdom.ORCID 0000-0003-4194-705X
Naima SmeuldersGreat Ormond Street Hospital for Children, London, United Kingdom.ORCID 0000-0002-2656-6593
Olga SlaterGreat Ormond Street Hospital for Children, London, United Kingdom.ORCID 0000-0002-5374-6303
J Ciaran HutchinsonGreat Ormond Street Hospital for Children, London, United Kingdom.ORCID 0000-0002-1708-2634
Neil SebireGreat Ormond Street Hospital for Children, London, United Kingdom.ORCID 0000-0001-5348-9063
Janet M ShipleyInstitute of Cancer Research , Sutton, United Kingdom.ORCID 0000-0001-6748-8678
Jarno DrostPrincess Máxima Center for Pediatric Oncology, Oncode Institute, Utrecht, the Netherlands.ORCID 0000-0002-2941-6179
Karin StraathofUCL Cancer Institute, London, United Kingdom.ORCID 0000-0001-9673-8568
Sam BehjatiWellcome Sanger Institute , Hinxton, United Kingdom.ORCID 0000-0002-6600-7665

Funding

NGTC - UCLOT2CA278730 · NCI · UNIVERSITY COLLEGE LONDON · PI PULE, MARTIN · 2022 to 2024
$3.6M
Bone Cancer Research Trust (BCRT) BCRT/5717Cancer Research UK (CRUK) CGCATF-2021/100014Cancer Research UK (CRUK) DRCPGM\100075European Research Council (ERC) ERC-CoG No 101170012HORIZON EUROPE Marie Sklodowska-Curie Actions (MSCA) No 885818National Cancer Institute (NCI) CA278730-01NCI NIH HHS OT2 CA278730NIHR Cambridge Biomedical Research Centre (NIHR Cambridge BRC) NIHR203312Wellcome TrustWellcome Trust (WT) 206194Wellcome Trust (WT) 220540/Z/20/AWellcome Trust (WT) 223135/Z/21/Z
6 · The paper itself

Abstract

Somatic mutations often predict survival in childhood cancers, as exemplified in rhabdomyosarcoma (RMS), in which FOXO1 gene fusion status is a key prognostic feature. In this study, we examined single-cell transcriptomes and discovered that cancer cells of lethal disease converge on a common cell state with a shared transcriptional landscape, irrespective of fusion status. Nuclear transcriptomics, chromatin accessibility, spatial transcriptomics, perturbation studies, and previously published datasets validated the overarching high-risk cell state. The convergent cell state only partially overlapped with transcriptional effects of the FOXO1 fusion and unexpectedly exhibited neural features. Overall, these findings delineate a cell state of high-risk RMS cells that transcends conventional molecular and histologic boundaries, suggesting an overarching disease phenotype that could transform target discovery and inform clinical practice. SIGNIFICANCE: Defining a convergent cell state of high-risk rhabdomyosarcoma that transcends existing histological and molecular features predictive of outcome provides biological insights into aggressive disease and uncovers potential biomarkers and therapeutic targets.

Indexed as

RhabdomyosarcomaBiomarkers, TumorForkhead Box Protein O1Gene Expression ProfilingGene Expression Regulation, NeoplasticHumansOncogene Proteins, FusionPrognosisSingle-Cell AnalysisSingle-Cell Gene Expression AnalysisTranscriptomeBiomarkers, TumorForkhead Box Protein O1FOXO1 protein, humanOncogene Proteins, Fusion

Identifiers

PMID42446905
PMCPMC13631504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.